Lipid nanoparticles
Formulation development for nucleic acids, peptides and other advanced payloads, with emphasis on composition–structure–performance relationships.
Nanomedicine · Formulation · Translation
Engineering Delivery.
Enabling Translation.
Jinbosen Bio develops practical drug-delivery and formulation technologies for biologics, nucleic acids and challenging molecules—from early formulation screening to translational development.
Lipid-based systemsLNPs, liposomes and phospholipid assemblies
Biological vesiclesExtracellular-vesicle formulation and processing
Translational focusFormulation, characterisation and development strategy
Technology platforms
We focus on delivery problems where formulation design, interfacial science and biological barriers determine whether a promising molecule can become a practical product.
Oral & mucosal delivery
Strategies addressing stability, permeability and biological barriers for macromolecules and other difficult-to-deliver actives.
Extracellular vesicles
EV isolation, formulation, stabilisation and translational evaluation for delivery and regenerative applications.
Development capabilities
Modular R&D packages can support feasibility assessment, formulation optimisation, analytical characterisation and partner-facing technical diligence.
Formulation screeningComposition, excipients, process parameters and design-of-experiments workflows.
Physicochemical characterisationParticle size, PDI, zeta potential, stability, morphology and payload-related attributes.
Barrier & performance studiesIn vitro stability, permeability, uptake and formulation–performance assessment.
Process & translation strategyScalability, critical quality attributes, comparability and development planning.
Business Development
Built for co-development, technical collaboration and technology transfer.
We work with biotechnology, pharmaceutical and research partners on clearly scoped technical programmes—from early proof-of-concept studies to formulation packages designed for further development or licensing discussions.
Contact Jinbosen Bio